Articles with public access mandates - Robert BastLearn more
OverallNIHCPRITCancer Research UKMRCNIHRNSFCSusan G. KomenWellcomeNSFDoDCIHRSNSFUSEDVAHHMIAHAFWFNHMRCFWOFRQSGenome CanadaDFGVillum FoundationSFITelethonVersus Arthritis, UKBBSRCBHFNational Centre for the Replacement, Refinement and Reduction of Animals in Research, UKParkinson's UKWorldwide Cancer Research, UKEuropean CommissionTarget Ovarian Cancer, UKDoris Duke Charitable FoundationGovernment of SpainGovernment of ItalyLymphoma Research Foundation, USAAIRC Foundation for Cancer Research in Italy
Not available anywhere: 14
Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway
J Chen, M Bai, C Ning, B Xie, J Zhang, H Liao, J Xiong, X Tao, D Yan, X Xi, ...
Oncogene 35 (19), 2506-2517, 2016
Mandates: National Natural Science Foundation of China
Low-grade serous carcinoma: new concepts and emerging therapies
I Romero, CC Sun, KK Wong, RC Bast Jr, DM Gershenson
Gynecologic oncology 130 (3), 660-666, 2013
Mandates: US National Institutes of Health
More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis
RC Bast, DR Spriggs
Gynecologic oncology 121 (3), 429-430, 2011
Mandates: US National Institutes of Health
Tumors: wounds that do not heal—a historical perspective with a focus on the fundamental roles of increased vascular permeability and clotting
HF Dvorak
Seminars in thrombosis and hemostasis 45 (06), 576-592, 2019
Mandates: US National Institutes of Health
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters
T Lyu, Y Jiang, N Jia, X Che, Q Li, Y Yu, K Hua, RC Bast Jr, W Feng
International journal of cancer 146 (6), 1553-1567, 2020
Mandates: National Natural Science Foundation of China
DIRAS3: an imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy, and tumor dormancy
G Bildik, X Liang, MN Sutton, RC Bast Jr, Z Lu
Molecular cancer therapeutics 21 (1), 25-37, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Inconsistent criteria used in American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
F Cardoso, M Saghatchian, A Thompson, E Rutgers
Journal of clinical oncology 26 (12), 2058-2059, 2008
Mandates: US National Institutes of Health
Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo
M Gao, Y Ma, RC Bast, Y Li, L Wan, Y Liu, Y Sun, Z Fang, L Zhang, ...
Medical oncology 33, 1-10, 2016
Mandates: National Natural Science Foundation of China
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β
C Yam, RK Murthy, GM Rauch, JL Murray, RS Walters, V Valero, ...
Investigational new drugs 36, 1103-1109, 2018
Mandates: US National Institutes of Health
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer—a study of the OVCAD consortium
N Heinzl, E Maritschnegg, K Koziel, C Schilhart-Wallisch, G Heinze, ...
Oncogene 42 (33), 2473-2484, 2023
Mandates: US National Institutes of Health, Research Foundation (Flanders), Cancer …
Combined purging approaches in autologous transplantation
EJ Shpall, RC Bast, CS Johnston, WP Peters, RB Jones
Bone Marrow Processing and Purging, 307-328, 2020
Mandates: US National Institutes of Health
The Role of Angiogenesis, Growth Arrest and Autophagy in Human Ovarian Cancer Xenograft Models for Tumor Dormancy
MN Sutton, Z Lu, RC Bast Jr
Tumor Dormancy, Quiescence, and Senescence, Vol. 3: Aging, Cancer, and …, 2014
Mandates: US National Institutes of Health
p27Kip1 as a Biomarker and Target for Treatment of Cancer
XF Le, RC Bast
Checkpoint controls and targets in cancer therapy, 215-233, 2009
Mandates: US National Institutes of Health
Corilagin Reduces Resistance to PARP Inhibitors by Inhibiting the ERK Signaling Pathway in Ovarian Cancers
B Luan, H Zhao, RC Bast, Z Lu, Y Yu
Mandates: National Natural Science Foundation of China
Available somewhere: 153
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
Mandates: Swiss National Science Foundation, US National Institutes of Health, US …
The biology of ovarian cancer: new opportunities for translation
RC Bast Jr, B Hennessy, GB Mills
Nature Reviews Cancer 9 (6), 415-428, 2009
Mandates: US National Institutes of Health
Rethinking ovarian cancer: recommendations for improving outcomes
S Vaughan, JI Coward, RC Bast Jr, A Berchuck, JS Berek, JD Brenton, ...
Nature Reviews Cancer 11 (10), 719-725, 2011
Mandates: US National Institutes of Health, Cancer Research UK
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
RG Moore, DS McMeekin, AK Brown, P DiSilvestro, MC Miller, WJ Allard, ...
Gynecologic oncology 112 (1), 40-46, 2009
Mandates: US National Institutes of Health
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria, RC Bast Jr, V Beral, ...
Nature reviews Cancer 15 (11), 668-679, 2015
Mandates: US National Institutes of Health, Cancer Research UK, UK Medical Research …
Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice …
LN Harris, N Ismaila, LM McShane, F Andre, DE Collyar, ...
Journal of Clinical Oncology 34 (10), 1134-1150, 2016
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program